## Edgar Filing: AGENUS INC - Form 4

AGENUS INC Form 4											
October 03, 20	Л								PPROVAL		
<b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b> Washington, D.C. 20549									3235-0287		
Check this b if no longer subject to Section 16.	F CHAN	NGES IN SECUI	Estimated burden ho	Estimated average burden hours per							
Form 5 obligations may continu	Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Res	ponses)										
1. Name and Address of Reporting Person <u>*</u> DECHAENE TOM			Symbol	er Name <b>an</b> US INC [		Trading	5. Relationship of Reporting Person(s) to Issuer				
(Last)	Middle)					(Check all applicable)					
(Last) (First) (Middle) C/O ANTIGENICS INC., 149 FIFTH AVENUE, SUITE 500			3. Date of Earliest Transaction (Month/Day/Year) 10/01/2014				X_ Director 10% Owner Officer (give title Other (specify below) below)				
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person				
NEW YORK,	NY 10010						Person	More than One R	Reporting		
(City)	(State)	(Zip)	Tab	le I - Non-J	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned		
	Transaction Date Ionth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D) Price	(Instr. 3 and 4)				
Reminder: Report	on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.				
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

## Edgar Filing: AGENUS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8	ĺ	Acquired (A Disposed of (Instr. 3, 4, 4 5)	f (D)				[]
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Shares $(1)$	\$ 3.193	10/01/2014		А		929.732		(1)	(1)	Common Stock	929.732

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
DECHAENE TOM C/O ANTIGENICS INC. 149 FIFTH AVENUE, SUITE 500 NEW YORK, NY 10010	Х						
Signatures							
Christine M. Klaskin, by Power of Attorney		10/03/20	014				
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Acquired under the Agenus Inc. Director Deferred Compensation Plan, as amended. Deferred shares represent an equal amount of the(1) Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.